Opens in new windowTelix Pharmaceuticals in advanced studies on prostate cancer: NierengartenOpens in new window07:13 · August 21, 2025 at 11:26AM EDT
Opens in new windowTension between FED members makes it tough for Powell: GwinnOpens in new window07:45 · August 21, 2025 at 11:21AM EDT
Opens in new windowCompanies are in better shape, despite tariffs: RubinOpens in new window05:16 · August 21, 2025 at 10:48AM EDT
Opens in new windowInvestors buying best fundamentally-driven stocks: SlimmonOpens in new window07:53 · August 21, 2025 at 10:38AM EDT
Opens in new windowLower rates could propel small caps: DietzeOpens in new window08:34 · August 21, 2025 at 10:03AM EDT
Opens in new windowMarket broadening is good sign: EllegardOpens in new window07:41 · August 21, 2025 at 9:32AM EDT
Opens in new windowGildan undervalued after Hanesbrands deal: SwartzOpens in new window07:06 · August 20, 2025 at 11:04AM EDT
Opens in new windowAI to boost financials, like Jackson Financial: VinokurOpens in new window09:03 · August 20, 2025 at 11:00AM EDT
Opens in new windowEconomic fundamentals deteriorating: PyleOpens in new window08:54 · August 20, 2025 at 10:06AM EDT
Opens in new windowWe're raising cash, taking gains on growth stocks: GardnerOpens in new window08:08 · August 20, 2025 at 9:36AM EDT